晚期前列腺癌未来临床研究路线图:APCCC 2024共识会议发现
APCCC 2024会议邀请120名专家对183个多选题进行投票,共识定义为专家组成员≥75%同意,结果143个(78%)问题未达共识。作者检索临床试验注册库识别正在进行的3期试验,发现部分证据缺口已有研究覆盖,但多个未达共识话题仍无临床试验。未达共识可能源于缺乏高级别证据、对现有数据解读不同或数据完全空白。
要点
- APCCC 2024专家投票中143/183(78%)问题未达共识,凸显晚期前列腺癌证据缺口。
- 部分未达共识领域已有正在进行的3期试验,但多个话题仍无临床试验。
- 未达共识原因包括缺乏高级别证据、数据解读差异或数据完全空白。
核心结论
- APCCC 2024大量问题未达共识,凸显晚期前列腺癌诊疗复杂性及生成稳健证据的紧迫性。
研究设计与样本
- 制定机构与方法:APCCC 2024会议邀请120名专家组成专家组,会前通过基于网络的调查对183个多选题进行投票,共识定义为专家组≥75%同意。
主要发现
- 143个(78%)问题未达共识。
- 作者检索clinicaltrials.gov和clinicaltrialsregister.eu,识别出多个可能解决部分证据缺口的正在进行的3期试验。
- 多个未达共识话题目前无临床试验在研究。
关键数值与推荐
- 共识阈值:专家组≥75%同意。
- 未达共识问题比例:143/183(78%)。
临床怎么用
- 临床医生应认识到晚期前列腺癌诸多领域缺乏高级别证据,实践决策需结合个体情况并关注正在进行的3期试验。
局限性
- 未达共识可能源于缺乏或有限的高级别证据、对现有数据解读不同或数据完全空白。
- 随着对前列腺癌生物学认识进步及新治疗靶点识别,可能发现更多不确定性领域。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Advanced Prostate Cancer Conference (APCCC) addresses many aspects of advanced prostate cancer management, including areas lacking high-level evidence. The 2024 APCCC conference defined consensus as ≥ 75 % agreement among the expert panellists, which was not reached for many questions. METHODS: An invited panel of 120 experts ("panellists") voted via a web-based survey on 183 multiple-choice questions prior to the APCCC 2024 conference. Consensus was not reached for 143 (78 %) of the questions, highlighting persistent evidence gaps. We reviewed clinicaltrials.gov and clinicaltrialsregister.eu to identify relevant ongoing phase 3 trials in these areas of non-consensus. RESULTS: Numerous ongoing phase 3 trials were identified that may help address some of the gaps identified by expert voting. However, several topics without consensus are not currently being investigated in clinical trials. CONCLUSIONS: Lack of consensus may stem from absent or limited high-level evidence, differing interpretations of existing data, or complete gaps in available data. The large number of questions without consensus at APCCC 2024 underscores the complexity of advanced prostate cancer care and the urgent need for trials generating robust evidence to guide practice. Furthermore, ongoing progress to improve our understanding of prostate cancer disease biology, including the identification of novel therapeutic targets, will likely identify additional areas of uncertainty. This manuscript highlights key directions for research by mapping areas without consensus against the landscape of current clinical trials.
引用
- Vogl UM, Merler S, Angrisani A, et al. A roadmap for future clinical research in advanced prostate cancer: Findings from the Advanced Prostate Cancer Consensus Conference (APCCC) 2024. Eur J Cancer. 2025. PMID: 41407614. doi:10.1016/j.ejca.2025.116131
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。